RosettaBlue(DE3) Competent Cells - Novagen

Genotype: endA1 hsdR17 (r_K12^– m_K12⁺) supE44 thi-1 recA1 gyrA96 relA1 lac (DE3) F′[proA⁺B⁺ lacI^qZΔM15::Tn10] pRARE (Cam^R, Tet^R)





This product contains genetically modified organisms (GMO). Within the EU GMOs are regulated by Directives 2001/18/EC and 2009/41/EC of the European Parliament and of the Council and their national implementation in the member States respectively. This legislation obliges us to request certain information about you and the establishment where the GMOs are being handled. Click here for Enduser Declaration (EUD) Form.

RosettaBlue host strains are NovaBlue derivatives that combine high transformation efficiency and recA endAlacI^q mutations with enhanced expression of eukaryotic proteins that contain codons rarely used in E. coli. These strains supply tRNAs for AGG, AGA, AUA, CUA, CCC, and GGA on a chloramphenicol-resistant plasmid. The tRNA genes are driven by their native promoters. Blue/white screening is not possible with RosettaBlue(DE3) strains due to the presence of the lacZ α-peptide coding sequence in the λDE3 prophage.

DE3 indicates that the host is a lysogen of λDE3, and therefore carries a chromosomal copy of the T7 RNA polymerase gene under control of the lacUV5 promoter. Such strains are suitable for production of protein from target genes cloned in pET vectors by induction with IPTG.

RosettaBlue host strains are NovaBlue derivatives that combine high transformation efficiency and with enhanced expression of eukaryotic proteins that contain codons rarely used in E. coli.

0.4 ml1 mlComponent

•2 × 0.2 ml5 × 0.2 mlRosettaBlue(DE3) Competent Cells

•2 × 2 ml4 × 2 mlSOC Medium

•2 ng2 ngTest Plasmid

Toxicity: Multiple Toxicity Values, refer to MSDS (O)

NOVAGEN is a registered trademark of Merck KGaA, Darmstadt, Germany